Previous 10 | Next 10 |
2023-11-28 10:35:11 ET More on Candel Therapeutics Candel Therapeutics jumps on Phase 2 data for cancer drug Seeking Alpha’s Quant Rating on Candel Therapeutics Historical earnings data for Candel Therapeutics Financial information for Candel Therapeut...
Decreases workforce by approximately 50% and reduces commercial manufacturing expenses to prioritize spend towards topline clinical data readouts for CAN-2409 in non-small cell lung cancer, pancreatic cancer, and prostate cancer in 2024 Prioritizes development of CAN-3110 in recurrent h...
2023-11-09 12:07:50 ET Candel Therapeutics press release ( NASDAQ: CADL ): Q3 GAAP EPS of -$0.29. Cash and cash equivalents as of September 30, 2023 were $43.0 million. Expects that its existing cash and cash equivalents will be sufficient to fund its current operating...
Initial survival data from phase 2 clinical trial of CAN-2409 in advanced non-small cell lung cancer (NSCLC) showed survival supportive of an increased tail on the maturing survival curve Initial data from phase 2 clinical trial of CAN-2409 in borderline resectable pancreatic cancer demon...
Histogen Inc. (HSTO) is expected to report for Q3 2023 News Corporation (NWSA) is expected to report $0.13 for Q1 2024 TORM plc (TRMD) is expected to report for Q3 2023 Blink Charging Co. (BLNK) is expected to report $-0.47 for Q3 2023 Nuvalent Inc. (NUVL) is expected to report $-...
Candel Therapeutics Inc. (CADL) is expected to report $-0.19 for Q3 2023
2023-11-06 14:17:01 ET More on Candel Therapeutics Seeking Alpha’s Quant Rating on Candel Therapeutics Historical earnings data for Candel Therapeutics Financial information for Candel Therapeutics For further details see: Candel Therapeutics jumps...
The first experimental agent from the enLIGHTEN™ Discovery Platform is Alpha-201-macro1, an investigational viral immunotherapy designed to activate innate immune surveillance Application of the enLIGHTEN™ Advanced Analytics suite to datasets from immune checkpoint inhibit...
Initial positive interim data revealed notable improvements in patients with borderline resectable pancreatic ductal adenorcarcinoma (PDAC) after experimental treatment with CAN-2409 Estimated overall survival rate was 71.4% at 36 months in CAN-2409 treated patients versus 16.7% in the co...
CAN-3110 is a first-in-class herpes simplex virus-1 oncolytic immunotherapy candidate with dual activity for oncolysis and immune activation in a single therapeutic In a first-in-human clinical trial of CAN-3110 in recurrent high-grade glioma, CAN-3110 was well tolerated and treatment...
News, Short Squeeze, Breakout and More Instantly...
Candel Therapeutics Inc. Company Name:
CADL Stock Symbol:
NASDAQ Market:
Candel Therapeutics Inc. Website:
2024-07-16 20:54:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-27 01:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
NEEDHAM, Mass., June 18, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL ), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that Paul Pete...